Skip to content

OCRA Board of Directors

Our Board

Distinguished leaders from fields including healthcare, law, entertainment, hospitality, and more make up our Board of Directors. While diverse in their areas of expertise, all of our members are united in their passion to advance ovarian and related gynecologic cancer research, help guide our path forward, and contribute toward our goal of finding a cure.

Related Topics

The Overview: November 2025

The Overview: November 2025

Friends, As we approach the end of the year, one thing stands out above all else: this is a moment of unprecedented opportunity to accelerate progress against ovarian and all gynecologic cancers. And thanks to you, OCRA is rising to meet that moment — driving innovation, expanding support, and providing the community that so many … Continued

Read more

OCRA Board Member Laura Shawver, PhD, Named to Fierce 50 of 2025

OCRA Board Member Laura Shawver, PhD, Named to Fierce 50 of 2025

Ovarian Cancer Research Alliance (OCRA) congratulates board member Laura Shawver, PhD, on her selection to the Fierce 50 of 2025, a leading industry award from Fierce Life Sciences recognizing individuals and organizations advancing what’s possible in health, science and patient care. Dr. Shawver was selected for her long-standing leadership in oncology research and drug development, … Continued

Read more

Make a Difference with OCRA on GivingTuesday

Make a Difference with OCRA on GivingTuesday

On GivingTuesday, YOU Can Help Shape the Future of Ovarian and Gynecologic Cancer Care Ovarian Cancer Research Alliance (OCRA) is the world’s largest organization combating ovarian and all gynecologic cancers through groundbreaking research, impactful advocacy, and unparalleled patient support while forging new paths in prevention, education, and awareness. We are deeply grateful to our community, … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.